Rangering i aksjer
#16392
AP Biosciences Inc. is a pioneering clinical-stage biopharmaceutical company... AP Biosciences Inc. is a pioneering clinical-stage biopharmaceutical company dedicated to the research and development of bispecific antibody drugs, aiming to fulfill critical unmet medical needs. Its robust pipeline features several promising candidates: Leading the pack, IBI302 is in Phase III clinical trials for the treatment of neovascular age-related macular degeneration (nAMD). Further along, AP505 is undergoing Phase I clinical trials for various solid tumors. AP203, also in Phase I, is being investigated for non-small cell lung cancer, head and neck squamous cell carcinoma, and esophageal squamous cell carcinomas. In earlier development, AP402 is currently in the pre-clinical research phase, focusing on breast cancer patients. Additionally, AP601 is also in pre-clinical research, targeting a broader spectrum of malignancies including lung cancer, pancreatic cancer, bladder cancer, ovarian cancer, and other solid tumors. Founded in 2013, the company maintains its headquarters in Taipei City, Taiwan.
Handel AP Biosciences Inc (6945)
Pris 6945 pris med markedsverdi på B
Markedsverdi av AP Biosciences Inc(6945)
Markedsverdi: $296.40M
Per September 2026 har AP Biosciences Inc en markedsverdi på $296.40M. Dette gjør AP Biosciences Inc til det 16392nd mest verdifulle selskapet i verden basert på markedsverdi ifølge våre data. Markedsverdi er den totale markedsverdien av et børsnotert selskaps utestående aksjer og brukes vanligvis til å måle hvor mye et selskap er verdt.
Markedsverdihistorikk for AP Biosciences Inc fra 2023 til 2026
6945 sammenlignet med topp 5 mest populære stocks
| Pris på 6945 |
|
Eiendel B |
Markedsverdi for B |
Resultater |
|
|
|
|
$5.260T
|
+1,774,392.01%
|
|
|
|
|
$4.779T
|
+1,612,085.39%
|
|
|
|
|
$4.017T
|
+1,355,071.84%
|
|
|
|
|
$3.719T
|
+1,254,724.12%
|
|
|
|
|
$2.734T
|
+922,380.34%
|
